Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting, single-administration post-operative analgesic
TEL AVIV, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company"), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, today announced expanded results from its previously reported preclinical study directly comparing its lead product candidate, PRF-110, to ZYNRELEF® (bupivacaine and meloxicam extended-release solution), an approved extended-release product used as a benchmark in the study. The expanded results characterize the pharmacokinetic (PK) and tissue-distribution properties of PRF-110 alongside the analgesic efficacy data previously announced.
PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed prior to closure. The product candidate is being developed to provide prolonged local analgesia following surgery through a single administration at the surgical site, with the goal of reducing the use of opioids for post-surgical pain.
The study was conducted in a validated porcine post-operative pain model, using von Frey methodology, to assess both analgesic efficacy and PK properties of the two extended-release formulations.
Key Findings
Comparable analgesic efficacy: PRF-110 and ZYNRELEF demonstrated similar reductions in mechanical sensitivity, as measured by the von Frey test, indicating comparable pain-relief performance.
Favorable pharmacokinetic profile: PRF-110 exhibited a slower absorption rate relative to ZYNRELEF, suggesting a more gradual release of ropivacaine at the site of administration.
Enhanced tissue retention: PRF-110 showed increased retention in local tissue along with higher local tissue exposure (Cmax), supporting prolonged availability of the active compound at the target site.
Sustained exposure: Both formulations demonstrated sustained systemic and local drug levels, reinforcing their potential as long-acting analgesic solutions.
"These expanded findings reinforce our confidence in PRF-110 as a differentiated, long-acting solution for post-operative pain management," said Efi Cohen-Arazi, Chief Executive Officer of PRF Technologies. "Its pharmacokinetic profile—characterized by slower absorption and enhanced local tissue retention—combined with analgesic efficacy comparable to an approved benchmark, potentially positions PRF-110 to address a significant unmet need in improving post-surgical recovery and patient comfort."